SCHEMBL26655421

SCHEMBL26655421

CN(C)C1CCN(c2ccc([N+](=O)[O-])c3c2CC(C)(C)O3)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 4/20 0.36
CTSB P07858 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CTPS1 P17812 1/20 0.35
WDR5 P61964 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
MAPK1 P28482 1/20 0.34
AR P10275 1/20 0.34
GAA P10253 1/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
TNNI3 P19429 1/20 0.34
TNNT2 P45379 1/20 0.34
TNNC1 P63316 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26655543 0.82 MAPT (0.47) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL26655610 0.82 ALDH1A1 (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL29661397 0.81 TIPARP (0.34) ALDH1A1MEN1KMT2AGAAUSP2
SCHEMBL24327498 0.81 TIPARP (0.34) ALDH1A1MEN1KMT2AGAAUSP2
SCHEMBL26655456 0.80 CTSB (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL29661331 0.78 CTSB (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL26655509 0.78 CTSB (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL29661420 0.78 CTSB (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL24327320 0.78 CTSB (0.40) ALDH1A1TDP1MAPTCTSBMEN1
SCHEMBL24327382 0.76 ALDH1A1 (0.42) ALDH1A1TDP1MAPTCTSBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
EP-4217348-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BeiGene, Ltd. (KY) 2023-08-02 EP disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 ALDH1A1 3986/4885TDP1 1830/4885MAPT 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.